You searched for "legislation"
IN FOCUS - Beyond 2020: what next for global eye health?
The year 2020 is a pivotal year for global eye health. It marks the conclusion of ‘VISION 2020: The Right to Sight’ which has guided action for the past two decades, and the end of the World Health Organization (WHO)...
Oral azithromycin for meibomian gland disease
Oral tetracyclines have been the traditional systemic treatment of blepharitis and acne rosacea, through inhibiting bacterial lipase production and reducing fatty acids. However, tetracyclines have a number of adverse side-effects and are required to be taken for a long duration...
Comparison of SS-OCT and SD-OCT in polypoidal choroidal vasculopathy
Swept source OCT (SS-OCT) is known to have a longer wavelength than spectral domain OCT (SD-OCT), allowing deeper penetration into retinal and choroidal layers. The aim of this study was to investigate whether SS-OCT is superior to SD-OCT in imaging...
OCT positioning regimen in macular hole surgery
The authors set out to evaluate an OCT-based positioning regimen for macular hole surgery. Patients were advised to maintain prone positioning until the hole was confirmed to be closed based on daily OCTs. Surgery consisted of 23-gauge phacovitrectomy with internal...
Macular atrophy with aflibercept
The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...
Atrophy and anti-VEGF
The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...
Corneal crosslinking in pellucid marginal degeneration
Fourteen studies were included in this first review examining the use of corneal-crosslinking (CXL) to treat pellucid marginal degeneration (PMD). PMD is a bilateral, non-inflammatory corneal thinning disorder characterised by inferior peripheral corneal thinning 1-3mm from the limbus in the...
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD
This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...
The effects of anti-VEGF therapy for NvAMD on retinal vasculature
This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...insitro and UK’s INSIGHT at Moorfields Eye Hospital announce collaboration to expand research efforts in neurodegeneration and related conditions
The world’s largest bioresource of eye images offers window into human health and serves as basis of a new AI foundation model to boost drug discovery. insitro, a machine learning-enabled drug discovery and development company, and the INSIGHT Health Data...
